
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel ...
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and …